Want to see HK:2367 full AI Analyst Report?
Top Page
Giant Biogene Holding Co. Ltd.
(2367)
Select Model
Select Model
Rating:73Outperform
Price Target:
HK$29.00
▲(0.83% Upside)
Action:Reiterated
Date:05/30/26
The score is driven primarily by strong financial quality (high profitability, very low leverage, and solid cash generation) tempered by 2025 revenue/earnings softness. Technicals remain a notable headwind with negative MACD and the price below longer-term moving averages, while reasonable valuation and a moderate dividend yield provide partial offset.
Positive Factors
Exceptional profitability
Very high gross and net margins indicate durable pricing power and a structurally advantaged product mix in biotech/consumer health. Strong operating profitability supports reinvestment, R&D and sustained cash generation even if revenue growth moderates, preserving long-term competitiveness.
Negative Factors
2025 revenue decline
A 12% revenue decline and falling net income signal meaningful demand softness or market saturation that can be structural rather than transitory. Sustained top-line weakness reduces scale economics, pressures margins, and can impair long-term investment in growth initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Exceptional profitability
Very high gross and net margins indicate durable pricing power and a structurally advantaged product mix in biotech/consumer health. Strong operating profitability supports reinvestment, R&D and sustained cash generation even if revenue growth moderates, preserving long-term competitiveness.
Read all positive factors
Giant Biogene Holding Co. Ltd. (2367) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$27.05B
Dividend Yield1.84%
Average Volume (3M)12.22M
Price to Earnings (P/E)12.2
Beta (1Y)1.27
Revenue Growth-0.47%
EPS Growth-11.25%
CountryHK
Employees1,758
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)1.83
Shares Outstanding1,061,704,000
10 Day Avg. Volume16,417,830
30 Day Avg. Volume12,220,358
Financial Highlights & Ratios
PEG Ratio-1.27
Price to Book (P/B)3.19
Price to Sales (P/S)5.73
P/FCF Ratio21.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$40.26Price Target Upside39.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)1.83
Revenue Forecast (FY)HK$6.07B
Giant Biogene Holding Co. Ltd. Business Overview & Revenue Model
Company Description
Giant Biogene Holding Co., Ltd. operates as an investment holding entity, primarily engaged in the research, development, production, and sale of beauty and wellness products based on bioactive materials throughout the People's Republic of China. ...
How the Company Makes Money
null...
Giant Biogene Holding Co. Ltd. Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
90
Very Positive
Cash Flow
78
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.52B | 5.54B | 3.52B | 2.36B | 1.55B |
| Gross Profit | 4.43B | 4.55B | 2.95B | 2.00B | 1.35B |
| EBITDA | 2.19B | 2.31B | 1.78B | 1.21B | 933.64M |
| Net Income | 1.91B | 2.06B | 1.45B | 1.00B | 828.13M |
Balance Sheet | |||||
| Total Assets | 10.85B | 8.04B | 4.97B | 3.14B | 7.88B |
| Cash, Cash Equivalents and Short-Term Investments | 8.29B | 5.86B | 3.78B | 2.20B | 7.26B |
| Total Debt | 9.69M | 6.71M | 2.73M | 2.59M | 7.68B |
| Total Liabilities | 917.03M | 918.14M | 602.03M | 301.19M | 6.86B |
| Stockholders Equity | 9.92B | 7.11B | 4.36B | 2.83B | 1.02B |
Cash Flow | |||||
| Free Cash Flow | 1.48B | 1.79B | 1.42B | 778.39M | 581.21M |
| Operating Cash Flow | 1.90B | 2.04B | 1.65B | 931.64M | 692.40M |
| Investing Cash Flow | -471.99M | -1.11B | -527.28M | -858.74M | 1.56B |
| Financing Cash Flow | 892.40M | 582.95M | 51.81M | -5.79B | 4.48B |
Giant Biogene Holding Co. Ltd. Technical Analysis
Negative
28.76
Price Trends
27.77
Negative
28.76
Negative
34.95
Negative
Market Momentum
-0.62
Positive
42.94
Neutral
51.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2367, the sentiment is Negative. The current price of 28.76 is above the 20-day moving average (MA) of 26.91, above the 50-day MA of 27.77, and below the 200-day MA of 34.95, indicating a bearish trend. The MACD of -0.62 indicates Positive momentum. The RSI at 42.94 is Neutral, neither overbought nor oversold. The STOCH value of 51.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2367.
Giant Biogene Holding Co. Ltd. Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$27.05B | 12.20 | 20.06% | 1.84% | -0.47% | -11.25% | |
71 Outperform | HK$10.13B | 7.95 | 42.42% | 2.53% | 35.28% | 41.20% | |
70 Outperform | HK$561.21M | 5.54 | 7.43% | 10.87% | -3.14% | -29.66% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
60 Neutral | HK$25.33B | 8.47 | 11.65% | 5.36% | 1.76% | 10.34% | |
51 Neutral | HK$16.74B | -48.55 | -4.30% | 5.00% | -1.71% | 53.04% | |
48 Neutral | HK$930.98M | 87.74 | -12.38% | ― | 52.36% | ― |
* Consumer Defensive Sector Average
HK:2367
Giant Biogene Holding Co. Ltd.
25.80
-29.23
-53.12%
HK:1044
Hengan International Group Co
21.82
0.63
2.98%
HK:3828
Ming Fai International Holdings
0.77
0.02
2.80%
HK:0157
Natural Beauty Bio-Technology
0.47
-0.09
-15.45%
HK:2145
Shanghai Chicmax Cosmetics Co., Ltd. Class H
25.44
-54.62
-68.22%
HK:6993
Blue Moon Group Holdings Ltd.
3.01
-0.88
-22.60%
Giant Biogene Holding Co. Ltd. Corporate Events
Giant Biogene Wins China Approval for First Recombinant Type III Collagen Neck Filler
Jun 17, 2026
Giant Biogene announced that its subsidiary Shaanxi Giant Biotechnology has received China’s medical device registration certificate for a cross-linked recombinant type III collagen implant designed for intradermal injection to correct moder...
Giant Biogene Shareholders Back All AGM Resolutions, Approve Final and Special Dividends
May 28, 2026
Shareholders of Giant Biogene Holding Co., Ltd. approved all resolutions at the 28 May 2026 annual general meeting, including the receipt of the 2025 audited results, re-election of three executive directors, authorisation of directors’ remu...
Giant Biogene Declares Final 2025 Cash Dividend and Sets HKD Payout Terms
May 28, 2026
Giant Biogene Holding Co., Ltd. has announced a final ordinary cash dividend of RMB 0.539 per share for the financial year ended 31 December 2025, following shareholder approval on 28 May 2026. The move underscores the company’s intention to...
Giant Biogene Updates Details of 2025 Special Dividend Payout
May 28, 2026
Giant Biogene Holding Co., Ltd. has updated details of a special dividend for the financial year ended 31 December 2025, confirming a payout of RMB 0.6714 per share, with the default payment for Hong Kong shareholders set at HKD 0.7707 per share b...
Giant Biogene Moves to Replace EY with KPMG as External Auditor
May 28, 2026
Giant Biogene has initiated a planned transition of its external auditor, moving from Ernst Young (EY), which has served for seven consecutive financial years, to KPMG as part of its efforts to align with good corporate governance practices. The ...
Giant Biogene Sets 2026 AGM to Refresh Board Mandates and Appoint New Auditor
May 6, 2026
Giant Biogene Holding Co., Ltd. has called its annual general meeting for 28 May 2026 in Xi’an, where shareholders will review the audited financial statements for the year ended 31 December 2025 and consider the re-election of three executi...
Giant Biogene Moves to Replace EY With KPMG as Auditor
Apr 30, 2026
Giant Biogene Holding Co. Ltd. has launched a planned change of auditors as part of its corporate governance review, deciding not to reappoint Ernst Young after seven consecutive years of auditing its consolidated financial statements. EY will co...
Giant Biogene Reshapes Corporate Secretariat With New Joint Company Secretary
Apr 8, 2026
Giant Biogene Holding Co. Ltd. announced that joint company secretary and authorised representative Ms. Yuen Wing Yan, Winnie has resigned from her roles, including as the company’s process agent in Hong Kong, effective 8 April 2026, with no...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.